2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 468

Initiation of Biologic Disease Modifying Antirheumatic Drug Therapy and Associated Changes in Disease Activity Measures in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort
Abstract Number: 862

iNKT Mediated Immunoregulatory Feedback Control Development of Autoimmune Arthritis in Mice
Abstract Number: 655

Innate Lymphoid Cells – New Players in Psoriatic Arthritis
Abstract Number: 1797

Insights from Treating to Target in Rheumatoid Arthritis at an Academic Medical Center
Abstract Number: 1725

Insulin-like Growth Factor Binding Protein-4 Exerts Anti-Fibrotic Effects and Its Levels Are Reduced in SSc-Associated Lung Fibrosis
Abstract Number: 619

Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
Abstract Number: 628

Integrated Efficacy Results from Two Phase 3 Trials of Ixekizumab for the Treatment of Psoriatic Arthritis
Abstract Number: 2806

Integrated Longitudinal Analysis Increases Precision and Reduces Bias: A Comparative 5-Year Analysis in the DESIR Cohort
Abstract Number: 2472

Integrated Phase 3 Safety Results of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Abstract Number: 616

Integrated Safety Summary of Tofacitinib in Psoriatic Arthritis Clinical Studies
Abstract Number: 770

Integrating Analysis of Skin RNA in Situ Hybridization Using Rnascope and Whole Skin Gene Expression in Systemic Sclerosis Skin to Localize Key Pathogenic Drivers of Skin Fibrosis
Abstract Number: 351

Integration of Electronically Captured Patient-Reported Outcomes in a Pediatric Rheumatology Clinic Visit
Abstract Number: 166

Integrative Systems Biology Approach Identifies Key Transcription Factors and Novel Rheumatoid Arthritis (RA) and Individualized Therapeutic Targets
Abstract Number: 203

Intensive Care Unit Admissions Among Patients with Rheumatic Diseases at a Tertiary Care Center
Abstract Number: 2552

Inter-Connections between Fatigue, Pain and Patient Global Assessement in Patients with Active Spondyloarthritis Followed in the Daily Clinic

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].